Management of Persistent Positive Tracheal Culture for A. baumannii

Introduction to Management

The American Thoracic Society recommends distinguishing between colonization and active infection in patients with persistent positive tracheal cultures for A. baumannii, and reassessing antimicrobial susceptibility patterns, optimizing antibiotic dosing and duration, considering adjunctive nebulized therapy, and implementing aggressive infection control measures 1, 2

Persistent positive cultures do not automatically indicate treatment failure or require antibiotic escalation, and patients who are clinically improving despite positive cultures likely represent colonization rather than persistent infection 1, 3
A. baumannii has a high propensity for airway colonization in mechanically ventilated patients without causing true infection 4, 3

The Infectious Diseases Society of America recommends reviewing current antibiotic dosing to ensure adequate drug exposure, with dosing regimens including meropenem 2g every 8 hours for carbapenem-susceptible isolates, and ampicillin-sulbactam 3g sulbactam every 8 hours for sulbactam-susceptible isolates 2, 5, 6
Combination therapy with two in vitro active agents is recommended for carbapenem-resistant A. baumannii with persistent infection 2, 5, 6

The American College of Chest Physicians recommends nebulized antibiotics for patients nonresponsive to systemic antibiotics, recurrent VAP, or isolates with MICs close to susceptibility breakpoint, with nebulized colistin dosing at 2-6 million IU daily 1

The Society for Healthcare Epidemiology of America recommends maintaining antimicrobial therapy for 2 weeks for severe infections such as VAP or bacteremia, especially with severe sepsis or septic shock 1, 2, 5

The Centers for Disease Control and Prevention recommend strict isolation measures with contact precautions, hand hygiene, and single room isolation to prevent transmission of A. baumannii 4, 3, 7, 8
Active screening with surveillance cultures from multiple sites is recommended to identify patients who become colonized 4, 3, 7, 8

The European Society of Clinical Microbiology and Infectious Diseases recommends avoiding tigecycline as monotherapy for bacteremia due to suboptimal serum concentrations and higher treatment failure rates, and avoiding carbapenems in monotherapy for severe infections in areas with high CRAB prevalence 2, 5
Monitoring renal function closely in all patients receiving colistin is recommended, as nephrotoxicity occurs in up to 33% of patients 2, 5

Place the patient in a single‑room isolation and apply contact precautions (gowns, gloves, dedicated equipment) to prevent transmission of A. baumannii in the intensive care setting. 9
Enforce strict hand‑hygiene practices for all healthcare workers interacting with the patient. 10
Clean the patient’s room and all reusable equipment with a 0.5 % sodium hypochlorite solution to eradicate environmental contamination. 10

Add nebulized colistin (2–6 million IU per day, divided every 8–12 hours) to systemic therapy when a respiratory component of A. baumannii infection persists despite adequate intravenous antibiotics. [11][12]
Use ultrasonic or vibrating‑plate nebulizers to achieve optimal aerosol delivery of colistin to the lower airways. [11][12]
Nebulized colistin must always be administered in combination with intravenous antibiotics; it should never be used as monotherapy for A. baumannii pneumonia. [11][12]